SEC Company Response from SOLIGENIX, INC. (SNGX) (CIK 0000812796) (SNGX) — Apr 15, 2009

SOLIGENIX, INC. (SNGX) (CIK 0000812796)
Date: April 15, 2009 · CIK: 0000812796 · Accession: 0000812796-09-000032

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-157322

Referenced dates: February 25, 2009

Date

February 13, 2009

Author

/s/

Form

CORRESP

Company

SOLIGENIX, INC. (SNGX) (CIK 0000812796)

Letter

letteronpreeffectiveamend.htm

Leslie J. Croland, P.A.

561.820.0212

fax 561.655.8719

lcroland@eapdlaw.com

April 14,

Via EDGAR and Facsimile (202) 772-9217

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-4561

Attn: Jeffrey P. Riedler

Re: DOR BioPharma, Inc.

Registration Statement on Form S-1 (the "Registration Statement")

Filed February 13, 2009

File No. 333-157322

Ladies and Gentlemen:

On behalf of DOR BioPharma, Inc., we are filing Pre-Effective Amendment No. 1 to the Registration Statement (the “Amendment”) in order to address the comment set forth in the letter dated February 25, 2009 from the staff (the “Staff”) of the United States Securities and Exchange Commission. The Amendment provides updated financial statements and financial information throughout the filing pursuant to Rule 8-08 of Regulation S-X. The Amendment also is being filed to register additional shares.

If the Staff has any questions or comments, please contact the undersigned at (561) 820-0212.

Sincerely,
/s/
Leslie J. Croland

Show Raw Text

CORRESP
1
filename1.htm

    letteronpreeffectiveamend.htm

              Leslie
      J. Croland, P.A.

              561.820.0212

              fax
      561.655.8719

              lcroland@eapdlaw.com

    April 14,
2009

    Via EDGAR and Facsimile
(202) 772-9217

    Division
of Corporation Finance

    United
States Securities and Exchange Commission

    100 F
Street, N.E.

    Washington,
D.C. 20549-4561

    Attn:                      Jeffrey
P. Riedler

    Re:           DOR
BioPharma, Inc.

    Registration Statement on Form S-1 (the
"Registration Statement")

    Filed February 13, 2009

    File No. 333-157322

    Ladies
and Gentlemen:

    On behalf
of DOR BioPharma, Inc., we are filing Pre-Effective Amendment No. 1 to the
Registration Statement (the “Amendment”) in order to address the comment set
forth in the letter dated February 25, 2009 from the staff (the “Staff”) of the
United States Securities and Exchange Commission.  The Amendment
provides updated financial statements and financial information throughout the
filing pursuant to Rule 8-08 of Regulation S-X.  The Amendment also is
being filed to register additional shares.

    If the
Staff has any questions or comments, please contact the undersigned at (561)
820-0212.

    Sincerely,

    /s/
Leslie J. Croland

    Leslie J.
Croland, P.A.

SecProbe.io